Cypress Proprietary Formulations Sample Clauses

Cypress Proprietary Formulations. Pierre Fabre agrees that the license granted to Cypress pursuant to Xxxxxxx 0.0 provides Cypress with the right to develop Cypress Formulations, subject to the following. The Steering Committee will establish business and technical criteria ("Selection Criteria") to be used by Cypress in determining whether a Cypress Formulation should be used instead of the IR Formulation or SR Formulation. Should the IR Formulation and SR Formulation fail to conform to the Selection Criteria, and should Cypress decide to develop any Cypress Formulation, Cypress will then notify Pierre Fabre of such Cypress Formulations, and the parties will negoxxxxx xx xxxd faith the grant by Cypress of an exclusive license to Pierre Fabre, its Affiliates and sub-licensees to register, market axx xxxx xxxx *Confidential Treatment Requested
Sample 1
AutoNDA by SimpleDocs
Cypress Proprietary Formulations. Xxxxxx Xxxxx agrees that the license granted to Cypress pursuant to Section 2.1 provides Cypress with the right to develop Cypress Formulations. The Steering Committee will establish business and technical criteria (“Selection Criteria”) to be used by Cypress in determining whether a Cypress Formulation should be used instead of the IR Formulation or SR Formulation. Should the IR Formulation or SR Formulation fail to conform to the Selection Criteria, and in the event that Cypress decides to develop any Cypress Formulation, Cypress will then notify Xxxxxx Xxxxx of such Cypress Formulations, and the parties will negotiate in good faith the grant by Cypress of an exclusive license under the Cypress Formulation Patents to Xxxxxx Xxxxx, its Affiliates and sub-licensees to register, market and sell such Cypress Formulations for the Rest of the World on commercially reasonable terms, provided that the royalty to be paid by Xxxxxx Xxxxx in consideration of the rights granted in Section 4.2 shall be included in the overall economic discussion. Cypress or its Affiliates or sub-licensees will own and control any intellectual property claiming Cypress Formulations, including, without limitation, the Cypress Formulation Patents.
Sample 1
Cypress Proprietary Formulations. Xxxxxx Xxxxx agrees that the license granted to Cypress pursuant to Section 2.1 provides Cypress and its sub-licensees with the right to develop and commercialize Cypress Formulations. Cypress, or its sub-licensee if Cypress grants such right to such sub-licensee, shall have the right to decide which formulation of Licensed Product to develop and commercialize in the Licensed Territory, based on the Selection Criteria. In the event that Cypress or any of its sub-licensees decides to develop any Cypress Formulation, rather than the IR Formulation or SR Formulation, based on the Selection Criteria, Cypress will then notify Xxxxxx Xxxxx of such Cypress Formulation(s), and the parties will negotiate in good faith the grant by Cypress of an exclusive license under the Cypress Formulation Patents to Xxxxxx Xxxxx, its Affiliates and sub-licensees to register, market and sell such Cypress Formulation(s) for the Rest of the World on commercially reasonable terms, provided that the royalty to be paid by Xxxxxx Xxxxx in consideration of the rights granted in Section 4.2 shall be included in the overall economic discussion. Cypress or its Affiliates or sub-licensees will own and control any intellectual property claiming Cypress Formulations, including, without limitation, the Cypress Formulation Patents.
Sample 1
Cypress Proprietary Formulations. Xxxxxx Xxxxx agrees that the license granted to Cypress pursuant to Section 2.1 provides Cypress with the right to develop Cypress Formulations, subject to the following. The Steering Committee will establish business and * Confidential Treatment Requested
Sample 1

Related to Cypress Proprietary Formulations

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Product The term “

  • Company Products Schedule 2.10(d) of the Company Disclosure Letter lists all Company Products, and for each such product or feature (and each version thereof) identifying its release date.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

Time is Money Join Law Insider Premium to draft better contracts faster.